Single dose of J&J’s Ad26.COV2.S vaccine effective against SARS-CoV-2 including in South Africa variant

By | April 26, 2021
One of these vaccines, the Ad26.COV2.S vaccine by Johnson & Johnson and Janssen, is a recombinant, replication-incompetent human adenovirus type 26 vector that encodes full-length SARS-CoV-2 spike protein in a prefusion-stabilized conformation.